- Home
- VRCA vs OTLK Comparison
VRCA vs OTLK Comparison
Compare VRCA & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRCA
- OTLK
- Stock Information
- Founded
- VRCA 2013
- OTLK 2010
- Country
- VRCA United States
- OTLK United States
- Employees
- VRCA N/A
- OTLK N/A
- Industry
- VRCA Biotechnology: Pharmaceutical Preparations
- OTLK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- VRCA Health Care
- OTLK Health Care
- Exchange
- VRCA Nasdaq
- OTLK Nasdaq
- Market Cap
- VRCA 43.0M
- OTLK 48.3M
- IPO Year
- VRCA 2018
- OTLK 2016
- Fundamental
- Price
- VRCA $0.42
- OTLK $1.44
- Analyst Decision
- VRCA Hold
- OTLK Strong Buy
- Analyst Count
- VRCA 5
- OTLK 5
- Target Price
- VRCA $6.00
- OTLK $10.20
- AVG Volume (30 Days)
- VRCA 243.3K
- OTLK 278.3K
- Earning Date
- VRCA 05-13-2025
- OTLK 05-19-2025
- Dividend Yield
- VRCA N/A
- OTLK N/A
- EPS Growth
- VRCA N/A
- OTLK N/A
- EPS
- VRCA N/A
- OTLK N/A
- Revenue
- VRCA $7,566,000.00
- OTLK N/A
- Revenue This Year
- VRCA $127.58
- OTLK N/A
- Revenue Next Year
- VRCA $88.06
- OTLK $288.46
- P/E Ratio
- VRCA N/A
- OTLK N/A
- Revenue Growth
- VRCA 47.66
- OTLK N/A
- 52 Week Low
- VRCA $0.38
- OTLK $0.87
- 52 Week High
- VRCA $11.41
- OTLK $9.25
- Technical
- Relative Strength Index (RSI)
- VRCA 39.53
- OTLK 48.17
- Support Level
- VRCA $0.45
- OTLK $1.52
- Resistance Level
- VRCA $0.48
- OTLK $1.62
- Average True Range (ATR)
- VRCA 0.04
- OTLK 0.10
- MACD
- VRCA -0.00
- OTLK -0.01
- Stochastic Oscillator
- VRCA 22.13
- OTLK 27.27
About VRCA Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.